Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Medical Genetics · Pompe Disease

Standard of Care and Treatment Options

At a Glance

Pompe disease is treated with enzyme replacement therapy, usually every two weeks, to help clear glycogen and stabilize muscle function. Babies with classic infantile-onset disease need urgent treatment, while symptom-free late-onset cases may be monitored before starting therapy.

Treatment for Pompe disease has been transformed by the development of Enzyme Replacement Therapy (ERT). This treatment provides a man-made version of the missing GAA enzyme, which travels through the bloodstream to the muscles to help clear the buildup of glycogen [1][2]. It is important to know that while ERT can stabilize the disease or slow decline, and improves survival remarkably in infants, it is not a cure and does not reliably reverse established damage.

The Urgency of Treatment in Infants

For infants with Classic Infantile-Onset Pompe Disease (IOPD), treatment is a medical priority. Because the heart and respiratory muscles can weaken rapidly, expert guidelines recommend starting ERT urgently as soon as the diagnosis is suspected or confirmed. While determining CRIM status is vital, lifesaving ERT should not ordinarily be delayed while waiting for a CRIM lab result; ITI planning should happen in parallel [3][4].

  • Immediate Start: Delaying treatment by even a few weeks can result in irreversible damage to the heart or lungs [3].
  • Early Success: When started early—sometimes within the first few days of life—ERT can significantly improve survival and help babies reach motor milestones like sitting and walking [5][6].

“Watch and Wait” for Late-Onset (LOPD)

If LOPD is discovered through newborn screening before any symptoms appear, doctors often recommend a “watchful waiting” approach rather than starting ERT immediately [7].

  • Monitoring: You will have regular appointments to check muscle strength, lung function, and biomarkers like CK [8].
  • Trigger for Treatment: For presymptomatic LOPD, ERT is typically considered through shared decision-making when a combination of serial motor assessments, functional trajectory, imaging, and respiratory changes indicate progression, rather than a single biomarker rise [5][3].
  • Standard Treatment: For adults who already have symptoms, ERT is the standard care to help stabilize muscle strength and breathing [9][10].

Enzyme Replacement Options

There are currently two main types of ERT used for Pompe disease:

  1. Alglucosidase alfa: The first approved treatment, typically given as an intravenous (IV) infusion every two weeks [2].
  2. Avalglucosidase alfa: A newer version designed to be more effectively absorbed by muscle cells. In clinical trials for LOPD, it was shown to be noninferior (at least as effective) to the original version [11][12].

Immune Tolerance Induction (ITI)

One of the biggest challenges in treating Pompe disease is the immune system’s reaction to the medicine. If the body has never seen the GAA protein (common in CRIM-negative patients), it may view the ERT as a “foreign invader” and create anti-drug antibodies (ADAs) that block the medicine from working [13][14].

To prevent this, doctors strongly recommend Immune Tolerance Induction (ITI) for CRIM-negative infants and high-risk CRIM-positive patients [15].

  • Common ITI Drugs: This often includes rituximab, methotrexate, and sometimes IVIG [16][17].
  • The Goal: ITI “teaches” the immune system to tolerate the ERT, ensuring the medicine can reach the muscles effectively. However, these drugs carry important risks, including profound immunosuppression and severe infection risk, requiring strict infection precautions and monitoring [18].
  • CRIM-Positive Patients: While the risk is lower, some CRIM-positive patients also develop high antibodies and may require an ITI protocol tailored to their risk [19][13].

Managing Your Infusions

ERT is given as an IV infusion, usually every two weeks, taking several hours each time.

  • Infusion-Associated Reactions (IARs): Some people experience mild reactions like fever, chills, or a rash during the infusion. These are usually managed by slowing the infusion rate or taking medications like antihistamines or fever-reducers beforehand [11][20].
  • Consistency is Key: Because the body constantly makes new glycogen, missing infusions can allow the buildup to return. Maintaining a consistent schedule is vital for long-term health, and you should never change treatment without specialist team oversight [9].
Scenario Typical Treatment Path
Classic IOPD Immediate ERT; ITI is strongly recommended if CRIM-negative or high risk [3][15].
Symptomatic LOPD Start ERT (alglucosidase or avalglucosidase) to stabilize function [9].
Presymptomatic LOPD Regular monitoring; start ERT based on shared decision-making when symptoms or confirmed functional changes appear [7][8].
High Antibody Titers May require “rescue” ITI or a change in the infusion regimen [21][22].

Common questions in this guide

What is the standard treatment for Pompe disease?
The standard treatment is enzyme replacement therapy, given through an intravenous infusion of alglucosidase alfa or avalglucosidase alfa, usually every two weeks. It helps clear glycogen from muscle cells and may stabilize the disease or slow decline, but it is not a cure and may not reverse established damage.
How quickly should babies with classic infantile-onset Pompe disease start treatment?
Babies with classic infantile-onset Pompe disease generally need enzyme replacement therapy urgently once the diagnosis is suspected or confirmed. Treatment usually should not wait for the immune-risk test called CRIM status; immune treatment planning can happen at the same time. Early treatment can improve survival and motor development.
Do people with symptom-free late-onset Pompe disease need enzyme therapy right away?
Not always. People with symptom-free late-onset Pompe disease are often monitored with muscle, motor, breathing, lung-function, and blood tests. The decision to begin treatment is usually made jointly with the care team when repeated assessments show meaningful progression rather than a single abnormal test.
What is immune tolerance induction in Pompe disease?
Immune tolerance induction uses medicines such as rituximab, methotrexate, and sometimes intravenous immunoglobulin to reduce the chance that the immune system will block enzyme replacement therapy. It is strongly considered for CRIM-negative infants and some high-risk CRIM-positive patients. Because it can weaken immune defenses, it requires careful infection monitoring.
What happens if I have a reaction during a Pompe infusion?
Some people develop fever, chills, or a rash during an infusion. The care team may slow the infusion and use medicines such as an antihistamine or fever reducer, depending on the reaction. Report symptoms promptly and do not change or skip treatment without guidance from the specialist team.
How often is enzyme replacement therapy given for Pompe disease?
Enzyme replacement therapy is usually given by intravenous infusion every two weeks, and each visit may take several hours. Keeping a consistent schedule helps limit renewed glycogen buildup. Your specialist team should guide any change to the schedule or infusion plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my child's estimated immune risk, what immune tolerance induction (ITI) protocol is recommended, and what are its specific infection risks?
  2. 2.Which enzyme replacement therapy (ERT) do you recommend—alglucosidase alfa or avalglucosidase alfa—and why is it the best fit for my specific situation?
  3. 3.If we are in a presymptomatic LOPD surveillance period, what combination of respiratory, functional, and biomarker changes would trigger a shared decision to begin ERT?
  4. 4.What is the protocol if I or my child has an infusion-associated reaction during an appointment?
  5. 5.How often will we check for anti-drug antibodies (ADAs), and what will we do if the titers become persistently high?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    c.1437G>A intron 9 substitution on acid α-glucosidase gene associated with classic infantile-onset Pompe disease phenotype.

    Morales A, Poling MI, Páez MT, et al.

    BMJ case reports 2015; (2015()).

    PMID: 26160551
  2. 2

    Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.

    Kishnani PS, Chien YH, Berger KI, et al.

    Molecular genetics and metabolism 2024; (143(1-2)):108559 doi:10.1016/j.ymgme.2024.108559.

    PMID: 39154400
  3. 3

    Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.

    Kronn DF, Day-Salvatore D, Hwu WL, et al.

    Pediatrics 2017; (140(Suppl 1)):S24-S45 doi:10.1542/peds.2016-0280E.

    PMID: 29162675
  4. 4

    [Clinical guidelines for infantile-onset Pompe disease].

    Pascual-Pascual SI, Nascimento A, Fernandez-Llamazares CM, et al.

    Revista de neurologia 2016; (63(6)):269-79.

    PMID: 27600742
  5. 5

    Disparities in late and lost: Pediatricians' role in following Pompe disease identified by newborn screening.

    Pillai NR, Fabie NAV, Kaye TV, et al.

    Molecular genetics and metabolism 2023; (140(1-2)):107633 doi:10.1016/j.ymgme.2023.107633.

    PMID: 37414610
  6. 6

    The earliest enzyme replacement for infantile-onset Pompe disease in Japan.

    Tocan V, Mushimoto Y, Kojima-Ishii K, et al.

    Pediatrics international : official journal of the Japan Pediatric Society 2022; (64(1)):e15286 doi:10.1111/ped.15286.

    PMID: 36074069
  7. 7

    Lessons from late-onset Pompe disease identified by Newborn screening: A systematic review.

    Boueri M, Doxey J, Boggs T, et al.

    Molecular genetics and metabolism 2026; (147(4)):109762 doi:10.1016/j.ymgme.2026.109762.

    PMID: 41719911
  8. 8

    Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

    Rairikar MV, Case LE, Bailey LA, et al.

    Molecular genetics and metabolism 2017; (122(3)):99-107 doi:10.1016/j.ymgme.2017.09.008.

    PMID: 28951071
  9. 9

    Recommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease.

    Domínguez-González C, Barba Romero MÁ, Caballero Eraso C, et al.

    Neurologia 2026; (41(2)):501933 doi:10.1016/j.nrleng.2025.501933.

    PMID: 41453611
  10. 10

    Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.

    , Al Jasmi F, Al Jumah M, et al.

    BMC neurology 2015; (15()):205 doi:10.1186/s12883-015-0412-3.

    PMID: 26471939
  11. 11

    Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.

    Diaz-Manera J, Kishnani PS, Kushlaf H, et al.

    The Lancet. Neurology 2021; (20(12)):1012-1026 doi:10.1016/S1474-4422(21)00241-6.

    PMID: 34800399
  12. 12

    Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.

    Kishnani PS, Díaz-Manera J, Illarioshkin S, et al.

    Journal of neurology 2025; (272(9)):581 doi:10.1007/s00415-025-13266-y.

    PMID: 40817977
  13. 13

    Insights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature review.

    Kishnani PS, Van Den Hout JMP, Hahn A, et al.

    Frontiers in immunology 2025; (16()):1690312 doi:10.3389/fimmu.2025.1690312.

    PMID: 41583481
  14. 14

    Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.

    Desai AK, Kazi ZB, Bali DS, Kishnani PS

    Molecular genetics and metabolism reports 2019; (20()):100475 doi:10.1016/j.ymgmr.2019.100475.

    PMID: 31193175
  15. 15

    Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.

    Kazi ZB, Desai AK, Berrier KL, et al.

    JCI insight 2017; (2(16)).

    PMID: 28814660
  16. 16

    High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.

    Poelman E, Hoogeveen-Westerveld M, Kroos-de Haan MA, et al.

    The Journal of pediatrics 2018; (195()):236-243.e3 doi:10.1016/j.jpeds.2017.11.046.

    PMID: 29428273
  17. 17

    A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.

    Gupta P, Shayota BJ, Desai AK, et al.

    Frontiers in immunology 2020; (11()):1929 doi:10.3389/fimmu.2020.01929.

    PMID: 33013846
  18. 18

    Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.

    Desai AK, Baloh CH, Sleasman JW, et al.

    Frontiers in immunology 2020; (11()):1727 doi:10.3389/fimmu.2020.01727.

    PMID: 32849613
  19. 19

    An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.

    Kazi ZB, Desai AK, Troxler RB, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(4)):887-895 doi:10.1038/s41436-018-0270-7.

    PMID: 30214072
  20. 20

    Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.

    Lessard LER, Tard C, Salort-Campana E, et al.

    Molecular genetics and metabolism 2023; (139(3)):107611 doi:10.1016/j.ymgme.2023.107611.

    PMID: 37285781
  21. 21

    Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.

    Chen HA, Hsu RH, Fang CY, et al.

    Frontiers in immunology 2024; (15()):1336599 doi:10.3389/fimmu.2024.1336599.

    PMID: 38715621
  22. 22

    Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.

    Schoser B, van der Beek NAME, Broomfield A, et al.

    European journal of neurology 2024; (31(9)):e16383 doi:10.1111/ene.16383.

    PMID: 38873957

This page explains Pompe disease treatment options for educational purposes and is not medical advice. Decisions about enzyme therapy, immune treatment, infusion reactions, and monitoring should be made with your metabolic or neuromuscular care team.

Get notified when new evidence is published on Glycogen storage disease due to acid maltase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.